Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer.

Fucci A, Colangelo T, Votino C, Pancione M, Sabatino L, Colantuoni V.

PPAR Res. 2012;2012:242498.

2.

Peroxisome proliferator-activated receptors in lung cancer.

Keshamouni VG, Han S, Roman J.

PPAR Res. 2007;2007:90289. doi: 10.1155/2007/90289.

3.
4.
5.

Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system.

Genini D, Catapano CV.

J Recept Signal Transduct Res. 2006;26(5-6):679-92. Review.

PMID:
17118805
6.

Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.

Sertznig P, Seifert M, Tilgen W, Reichrath J.

Am J Clin Dermatol. 2008;9(1):15-31. Review.

PMID:
18092840
7.
8.

Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.

Guan Y.

Minerva Urol Nefrol. 2002 Jun;54(2):65-79. Review.

PMID:
12185990
9.
10.

Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise.

Sertznig P, Reichrath J.

Dermatoendocrinol. 2011 Jul;3(3):130-5. doi: 10.4161/derm.3.3.15025.

11.

Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.

Giaginis C, Tsantili-Kakoulidou A, Theocharis S.

Fundam Clin Pharmacol. 2007 Jun;21(3):231-44. Review.

PMID:
17521292
12.

[Peroxisome proliferator-activated receptors and atherosclerosis].

Jin N, Wang X.

Sheng Li Ke Xue Jin Zhan. 2004 Jan;35(1):13-8. Review. Chinese.

PMID:
15127591
13.

Biology and therapeutic applications of peroxisome proliferator- activated receptors.

Menendez-Gutierrez MP, Roszer T, Ricote M.

Curr Top Med Chem. 2012;12(6):548-84. Review.

PMID:
22242855
14.

Peroxisome proliferator-activated receptors and inflammation.

Moraes LA, Piqueras L, Bishop-Bailey D.

Pharmacol Ther. 2006 Jun;110(3):371-85. Review.

PMID:
16168490
15.

PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.

Peyrou M, Ramadori P, Bourgoin L, Foti M.

PPAR Res. 2012;2012:757803.

16.
17.

Peroxisome proliferator-activated receptor and vitamin d receptor signaling pathways in cancer cells.

Matsuda S, Kitagishi Y.

Cancers (Basel). 2013 Oct 21;5(4):1261-70. doi: 10.3390/cancers5041261.

18.

PPAR: a mediator of peroxisome proliferator action.

Green S.

Mutat Res. 1995 Dec;333(1-2):101-9. Review.

PMID:
8538617
19.

PPARs and the kidney in metabolic syndrome.

Ruan X, Zheng F, Guan Y.

Am J Physiol Renal Physiol. 2008 May;294(5):F1032-47. doi: 10.1152/ajprenal.00152.2007. Review.

20.

PPAR Ligands for Cancer Chemoprevention.

Yasui Y, Kim M, Tanaka T.

PPAR Res. 2008;2008:548919. doi: 10.1155/2008/548919.

Items per page

Supplemental Content

Support Center